Results 101 to 110 of about 4,690 (200)

The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor. [PDF]

J Pediatr Gastroenterol Nutr
Sermet-Gaudelus I, Sadrieh P, Bonnel AS, Enaud R, Wizla N, Languepin J, Nangui A, Deelawon A, Rave J, Dabelow S, Barucha A, Zagoya C, Duckstein F, Mainz JG.   +13 more
europepmc   +1 more source

Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis. [PDF]

Eur Respir J
Halle O, Graeber SY, Kontsendorn J, Kessemeier C, Falke JN, Schwabe J, Schütz K, Pallenberg ST, Dalferth R, Grychtol R, Ringshausen FC, Stahl M, Thee S, Roehmel JF, Syunyaeva Z, Duerr J, Chung J, Hirtz S, Uselmann T, Kühbandner I, Rückes-Nilges C, Bagheri-Pothoff A, Barth S, Schaub B, Brinkmann F, Weber S, van Koningsbruggen-Rietschel S, Abdo M, Weckmann M, Widder S, Hansen G, Tümmler B, Sommerburg O, Naehrlich L, Mall MA, Dittrich AM.   +35 more
europepmc   +1 more source

Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment. [PDF]

J Patient Rep Outcomes
Buniotto F, Tridello G, De Scolari A, Meneghelli I, Pintani E, Perobelli S, Cipolli M.   +6 more
europepmc   +1 more source

Impact on Body Composition After Two Years of Elexacaftor-Tezacaftor-Ivacaftor Therapy in Children with Cystic Fibrosis. [PDF]

Children (Basel)
Álvarez Merino M, Cárdenes CML, Cavia SM, Rubio ET, Rodríguez-Martínez A, Santamaría SV, Torne CV, Beltrán MÁ, Galindo CG, Garriga García M, Alonso AM, Hurtado MM, Sierra San Nicolás S, Ortiz-Pérez P, Gutiérrez Martínez JR, González MS, Jiménez DG, Martín JJD.   +17 more
europepmc   +1 more source

Modulation of immune responses by elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis: data from a compassionate use program. [PDF]

Respir Res
Lucca F, Pianazzola A, Meneghelli I, Catanzaro G, Sabbioni G, Tridello G, Hristodor AM, De Luca E, Menichetti G, Breveglieri G, Altieri MT, Bordicchia M, Fabrizzi B, Ferretti E, Lippi G, Ros M, Borgatti M, Cipolli M, Bezzerri V.   +18 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis. [PDF]

Pediatr Pulmonol
Trost SU, Harindhanavudhi T, Wang Q, Ankireddypalli A, Simrah A, Avula S, Moheet A.   +6 more
europepmc   +1 more source

Cystic fibrosis liver disease progression in the era of elexacaftor-tezacaftor-ivacaftor. [PDF]

JHEP Rep
Mouliade C, Parlati L, Tzedakis S, Collier M, Bouam S, Vallet-Pichard A, D'Halluin-Venier V, Kanaan R, Pol S, Sogni P, Burgel PR, Mallet V, Demosthenes Research Group.   +12 more
europepmc   +1 more source

Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Kogias C, Sopiadou A, Fouzas S, Vantsi P, Chrysochoou EA, Desli E, Galogavrou M, Gasparis N, Hatziagorou E.   +8 more
europepmc   +1 more source

"An Amazing Transformation!" The Lived Experiences of Elexacaftor/Tezacaftor/Ivacaftor in Adults with Cystic Fibrosis.

Respiration
Chapman N, Vekaria S, Hill K, Cavalheri V, Mulrennan S, Gucciardi DF.   +5 more
europepmc   +1 more source

Comprehensive Evaluation of Elexacaftor/Tezacaftor/Ivacaftor in Paediatric Cystic Fibrosis: Nutritional, Pulmonary, and Quality-of-Life Outcomes. [PDF]

J Clin Med
Walicka-Serzysko K, Postek M, Mielus M, Borawska-Kowalczyk U, Milczewska J, Zybert K, Wozniacki Ł, Wołkowicz A, Sands D.   +8 more
europepmc   +1 more source